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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Does 
sertraline decrease depression in patients who suffered a traumatic brain injury (TBI)?” 
 
STUDY DESIGN: Review of three randomized controlled trials (RCTs) published in English 
between 2009-2016. 
 
DATA SOURCES: One RCT and two double-blind, placebo-controlled, RCTs found via 
PubMed evaluated the benefit of the antidepressant drug, sertraline (Zoloft), in decreasing 
depression in patients who suffered a TBI. 
 
OUTCOMES MEASURED: Main outcomes were measured using the DSM-IV, Hamilton 
Rating Score for Depression (HAM-D)6, Beck Anxiety Inventory (BAI)6, and the Life-3 quality 
of life (QOL)6, Mini-International Neuropsychiatric Interview7, Patient Health Questionnaire-9 
(PHQ-9)9 and World Health Organization QOL (WHOQOL)9. 
 
RESULTS: Ashman, Cantor, Gordon, et al.6 found that 59% of patients receiving sertraline were 
treatment responders with a NNT=4 x2=3.1 and p=0.08, making these findings statistically 
insignificant. Jorge, Acion, Burin et al.7 reported that the likelihood of post-TBI depression was 
4.6 times more likely in the placebo group than in the group receiving sertraline with a NNT=6, 
NNTB=4, and the NNH=73, (p=0.03). Ansari, Jain, Sharma et al.9 recorded an improvement of 
9.55 in mean PHQ-9 scores from baseline (p= 0.04) and a 16.3-22.1% improvement in mean 
WHOQOL scores from baseline in the group receiving sertraline, with statistically significant 
differences in WHOQOL domains 1-3. 
 
CONCLUSIONS: There was evidence in all 3 studies to support the benefits of sertraline in 
decreasing post-TBI depression. However, only two studies provided statistically significant 
data. Based on the findings in the two studies that reported data with statistical significance, 
sertraline does decrease depression in patients who suffered a TBI. More specifically, there is 
also significant evidence that supports the prophylactic use of sertraline to prevent post-TBI 
depression. 
 
KEY WORDS: Traumatic Brain Injury, Sertraline 
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INTRODUCTION 
Depression is a mood disorder characterized by a depressed mood or a loss of interest in 
activities that one used to enjoy (anhedonia), which is often accompanied by feelings of guilt, a 
change in sleep, weight, energy, cognition, concentration, psychomotor behavior, and homicidal 
or suicidal ideation.1 A multitude of biopsychosocial and genetic factors have been found to a 
play a role in the etiology of depression such as trauma, family history, substance abuse, divorce, 
pregnancy, and certain medications. Additionally, correlations exist between depression and 
chronic medical conditions such as multiple sclerosis, rheumatoid arthritis, cardiovascular 
disease, cerebrovascular disease, and traumatic brain injury (TBI).1 
A TBI is defined as, “an alteration in brain function, or other evidence of brain pathology, 
caused by an external force”2. This injury may be due to any direct or indirect, angular or 
rotational force to the head or neck that is powerful enough to cause shear stress on brain tissue 
and blood vessels.3 It is unknown what exact pathological changes produced by a TBI directly 
cause depressive symptoms, however, it is known that a TBI causes alterations in brain 
functioning due to biochemical cascades leading to cell death. A forceful injury to the head can 
cause cellular strain and deformation of brain tissue leading to two molecular responses. One is 
the release of the neurotransmitter glutamate, which increases intracellular calcium leading to 
cytotoxicity and cell death.2 Second, is a change in the ionic equilibrium in neuronal cell 
membranes. Either cellular response can lead to immediate cell death or, over time, the neuron 
may repair itself.2 Since there is no way to predict which cells will die or regenerate, defining the 
severity or prognosis of a TBI is challenging, however, knowing the mechanism of injury is 
useful. In determining which regions of the brain were most likely damaged based on the 
directional forces, there can be potential relationships drawn between the pathology and 
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symptomology. For example, orbital-frontal brain damage has been linked to irritability, frontal 
regions to impulsivity, and frontal and temporo-limbic regions to depression.2 
The pathophysiology of depression is not well understood but has been attributed to an 
alteration in neurotransmitters such as serotonin, histamine, dopamine, norepinephrine, and 
epinephrine. Alterations in neuroendocrine functioning have also been linked to depression such 
as increased levels of cortisol and corticotropin-releasing hormone (CRH), as well as a decreased 
response of thyroid stimulating hormone (TSH) to thyroid releasing hormone (TRH).4 The 
widespread etiology and complex pathophysiology behind depression is what makes treating this 
disorder challenging.  
The gold standard treatment for depression is the class of medications known as selective 
serotonin reuptake inhibitors (SSRIs), such as sertraline, paroxetine, and fluoxetine. Other 
medication classes such as SNRIs, NRDIs, NaSSAs, TCAs, and MAOIs are also used, as well as 
psychotherapy, electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS).1 
Most often, treatment modalities consist of a combination of the therapies described above. 
Common treatments for a TBI include pain relievers (naproxen, ibuprofen, acetaminophen etc.), 
strict restriction of activity/stressors (exercise, reading, school, work, loud noises, bright lights, 
social/family stressors), and also vitamins such as melatonin, B12, and fish oil.3 
A range of 6-77% of those who experience a TBI go on to suffer from depressive 
disorders.5 Within this range, 25-50% will suffer post-TBI depression within the first year and 
26-64% of these patients will suffer from lifetime depression.5 Post-TBI depression has been 
correlated to functional disability, decreased participation in activities of daily living, sexual 
dysfunction, lower ratings of health and QOL, reduced employment, and increased rates of 
suicidal ideation.6 There is an estimated 2.5 million to 6.5 million people who suffer from a 
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disability post-TBI, which is associated with an estimated total annual cost of $60 billion.7 The 
yearly incidence of TBIs in the US is about 1.7 million7, but in the past 5 years, annual rates for 
TBI-related ER visits, hospitalizations, and deaths have been recorded as high as 2.8 million.8 
About 30% of patients seen by their primary care physicians report depressive 
symptoms.1 It is important to know if these symptoms are related to a TBI because it will change 
patient management. Using sertraline for post-TBI depression is efficacious due to the drugs 
specific mechanism of action. As previously mentioned, TBIs cause neuronal damage and cell 
death, which results in alterations in cellular communication pathways and neuronal release, with 
the potential of decreasing normal serotonin levels. Sertraline inhibits the reuptake of serotonin 
by presynaptic neurons, which increases the amount of serotonin in the brain.  
Physician assistants (PAs) play a vital role in assessing and treating psychological illness. 
Post-TBI depression is relevant to patients and the PA practice because it is a prevalent cause of 
morbidity and mortality. Improvements in patient QOL and healthier outcomes can be achieved 
by implementing the use of sertraline for the treatment or prevention of post-TBI depression. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not “Does 
sertraline decrease depression in patients who suffered a traumatic brain injury (TBI)?” 
METHODS 
One RCT and two double-blind, placebo-controlled, RCTs were found via PubMed using 
specific inclusion criteria for this review. The patient population is patients 18 years and older 
who suffered a TBI. The intervention studied was oral sertraline. The control group used for 
comparison were patients 18 years and older who suffered a TBI and did not receive sertraline. 
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Outcomes measured were improvements in depressive symptoms, QOL, and prevention of 
depression in patients post-TBI. 
DATA SOURCES: 
 Keywords that were used to search for articles were “traumatic brain injury” and 
“sertraline”. Each article consisted of published data written in the English language. Articles 
were selected based on their relevance to the clinical question and were required to have patient-
oriented evidence that matters (POEMs). The inclusion criteria for articles used in this review 
were as follows: RCTs with outcomes that were POEMs, published after 2009, participants 
above the age of 18 who suffered a TBI, the use of PO sertraline as an intervention. Studies that 
were excluded from this review were studies that were not RCTs, studies without POEMs, 
published before 2009, used patients under the age of 18, and who used patients who did not 
meet criteria for a TBI. Statistics reported included the following: p-value, mean (x̄), standard 
deviation (SD), chi-square (x2), odds ratio (OR), F-statistic (F), confidence interval (CI), relative 
benefit increase (RBI), absolute benefit increase (ABI), numbers needed to treat (NNT), numbers 
needed to treat to benefit (NNTB), and numbers needed to harm (NNH). See Table 1 for 
demographics and inclusion/exclusion criteria for the articles used in this review. 
OUTCOMES MEASURED 
 The outcomes measured in all of the studies were POEMs. Ashman, Cantor, Gordon et 
al.6 measured the efficacy of sertraline in the treatment of post-TBI depression using the HAM-
D, BAI, and Life-3 QOL. Jorge, Acion, Burin et al.7 measured the time to onset and the 
prevention of depressive disorders post-TBI using the Mini-International Neuropsychiatric 
Interview and DSM-IV criteria. Ansari, Jain, Sharma et al.9 measured the treatment of depression 
and improvements in QOL using the PHQ-9 and WHOQOL questionnaire. 
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Table 1: Demographics and Characteristics of Articles Reviewed 
Study Type #Pts Age Inclusion Exclusion W/D Intervention 
Ashman6 
(2009) 
RCT, 
double 
blind 
52 18+ 18 years or older, hx of 
TBI with a documented 
LOC/ evidence of a TBI 
(ie, pathology on 
neuroimaging); At least 
6 months post-injury; dx 
criteria for a major 
depressive episode 
(DSM-IV); score 18 or 
greater on the HAM-D; 
Be able to comprehend 
or answer verbal/written 
questionnaires 
Suspected to be using antidepressant 
medication; Currently in 
psychotherapy; have active suicidal 
plans or depression severe enough to 
require hospitalization; have a 
serious medical illness; pregnant or 
breast-feeding; mass brain lesions or 
other neurologic diagnoses other 
than TBI; history of current or past 
psychosis or mania using DSM-IV 
criteria; current substance abuse 
disorder using DSM-IV criteria; 
history of clinically significant liver 
or renal disease.  
11 Sertraline PO qd 
x10w; 25mg QD x 
2w; adjusted @ 
end of week 2 & 
q2 weeks after 
 
Range of 25 to 
200mg/d 
depending on 
clinical response 
and tolerance by 
the end of the 
clinical trial 
Jorge7 
(2016)  
RCT, 
double 
blind 
94 18-
85 
Met Center for Disease 
Control (CDC) criteria 
for TBI; Mild, 
Moderate, or Severe 
TBI as categorized by 
initial Glasgow Coma 
Scale (GCS) scores; 
Complete recovery from 
Post Traumatic Amnesia 
(PTA) within 4 weeks of 
the traumatic episode. 
 
Penetrating head injuries; Clinical or 
neuro-radiological evidence of 
spinal cord injury; severe 
comprehension deficits; previous 
cognitive decline consistent with 
dementia; DSM-IV mood, anxiety or 
psychotic disorder (pts with a hx of 
alcohol abuse or alcohol dependence 
during the year preceding TBI are 
still included in the study); PO 
antidepressants at the time of TBI or 
6 month period prior to; failed a 
previous trial of sertraline/ SE that 
prompted the drug to be d/c; 
Pregnancy; plan to become 
pregnant; Severe complicating 
illness such as neoplastic ds or 
uncompensated heart, renal or liver 
failure. 
15 Sertraline, 25 mg, 
PO, QD x 5 days 
50 mg, PO QD x 
5d 
100 mg, PO, QD x 
the remainder of 
the 24-week 
trial/until 
development of 
mood disorder  
Ansari9 
(2014) 
RCT 89 18+ Male pts 18 years or 
older with a hx of TBI 
with a documented LOC 
or other evidence of a 
TBI (determined by 
pathology on 
neuroimaging); 
comprehend or answer 
verbal/written 
questionnaires; 2-week 
old injury 
Females, Dx of a serious medical 
illness, substance abuse disorder 
(DSM-IV); Men with a mass lesions 
or other neurologic dx other than 
TBI; Men who have a hx of current 
or past psychosis or mania, major 
depressive disorder (MDD) or any 
other mental disorder except current 
depression, clinically significant 
liver or renal ds.  
9 Sertraline, 50mg 
PO QD x 24 weeks 
 
RESULTS 
Ashman, Cantor, Gordon, et al6 conducted a double-blind RCT to study the efficacy of 
sertraline in the treatment of post-TBI depression. Their study consisted of 52 participants with a 
mild, moderate, or severe TBI, a diagnosis of major depression disorder (MDD), and a baseline 
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HAM-D score of 18 or greater. The study was conducted at a research center where physicians 
visited participants every 2 weeks to collect data in the form of HAM-D, Life-3, and BAI 
questionnaires. Response to treatment was determined by a reduction of a HAM-D score by 
50%. In the experimental group, 59% were considered treatment responders, while only 32% in 
the control group with a x2 value of 3.1 and a p-value of 0.08.6 The NNT in this study was 4. 
These results are further illustrated in Table 2.  
Table 2. Treatment Responders Using HAM-D Scores6 
CER EER RBI ABI NNT 
32% 59% 84.4% 27% 3.7 (4) 
CER= Control Event Rate; EER= Experimental Event Rate; RBI= Relative Benefit Increase; ABI= Absolute Benefit Increase 
The experimental group showed decreased BAI scores and increased Life-3 scores after 
the 10-week trial with mean change from baseline scores of 12.1 and 3.5 respectively, but when 
compared to control groups these changes were not significant (p > 0.05).6 Out of the 52 
participants who started the study, 11 dropped out, 3 of which were removed for clinical reasons. 
One participant in the treatment group was removed due to increased depression. In the placebo 
group, two were removed due to increased anxiety and a mild allergic reaction. The other 8 were 
noncompliant. The intent to treat analysis found significant differences between the last HAM-D 
score of dropouts and the HAM-D scores of those who remained, with dropouts having higher 
HAM-D scores with an F-score of 4.0 and p-value of 0.05.6 There were no adverse events (AEs) 
or comments on safety/tolerability reported in the 41 participants who completed the study. 
Jorge, Acion, Burin et al7 conducted a double-blind RCT using 94 patients who had 
suffered a mild, moderate, or severe TBI to determine the efficacy of preventing the onset of a 
depressive disorder using sertraline. Patients with ongoing depression were excluded from the 
study and participants with a history of mood disorders were required to be in remission for at 
least 1 year. Patients were evaluated in person at weeks 2, 4, 8, 12, 16, 20, and 24-weeks and via 
telephone interviews at 6, 10, 14, 18, and 22-weeks. Out of the 94 patients, 48 received sertraline 
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and the rest received a placebo. The dosing regime of sertraline can be found in Table 1. The 
diagnosis of depression was made by experienced psychiatrists using the Mini-International 
Neuropsychiatric Interview and DSM-IV criteria. After 24-weeks, it was determined that the 
NNT in order to prevent the onset of a depressive disorder post-TBI using sertraline was 6, the 
NNTB was 4, and the NNH was 73.7 The likelihood (x2) of developing a depressive disorder was 
4.6 times higher in the placebo group (p=0.03).7 These results are organized in Table 3.  
Table 3. NNT to Prevent a Depressive Disorder: Risk Comparison7 
 NNT NNTB NNH 95% CI x2 p-value 
Week 24 5.9 (6) 3.1 (4) 72.1 (73) 3.1-71.1 4.6 0.03 
 
AEs were also considered in this study; however, only two AEs were determined to be 
higher in the experimental group versus the placebo. The OR for diarrhea was 2.3 (p=0.1) and 
the OR for dry mouth 7.2 (p=0.01) in the experimental group using a 90% CI. See Table 4. 
Table 4. Adverse Events7 
Adverse Event Odds Ratio 90% CI P-value 
Diarrhea  2.3 1.0-5.5 0.1 
Dry mouth 7.2 1.9-27.6 0.01 
 
Although sexual dysfunction is one of the most common AEs associated with SSRIs, it 
was determined to be insignificant in this study with a mean and SD of 13.9 and 5.8 in the 
experimental group and 12 and 3.6, respectively in the placebo group displayed in Table 5.  
Table 5. Sexual Dysfunction7 
 Sertraline Placebo 
ASEX a mean (SD) 13.9 (5.8) 12.0 (3.6) 
a Sexual dysfunction was scaled using the Arizona Sexual Experience Scale (ASEX) 
 
 Ansari, Jain, Sharma et al.9 conducted a RCT on 80 male participants who suffered either 
a mild or moderate TBI and who were determined to be depressed. This study was carried out in 
a neurosurgery ward and excluded women to maintain homogeneity among the group. Half of 
the participants were given sertraline and the control group did not receive a placebo. The mean 
score and SD of the PHQ-9 at the beginning of the study was 14.88 and 3.6 in the intervention 
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group and 13.2 and 3.1 in the control group, respectively.9 At the end of the 24-week study, there 
was a significant improvement in mean scores in the experimental group compared to the control 
group with a mean and SD of 5.33 and 2.98 in the experimental and 6.29 and 3.2 in the control 
group (p=0.04).9 The mean change from baseline in the experimental group was 9.55, which is 
considered large for this type of study. This data is organized into Table 6. 
Table 6. Improvement in Depression Determined by PHQ-9 Scores9 
 Sertraline  Control 
Baseline 14.88 (3.6)a 13.2 (3.1)a 
24 Weeks 5.33 (2.98)b 6.29 (3.2)b 
Mean change from baseline 9.55 6.91 
Data recorded as mean (SD); a p-value= 0.22; b p-value= 0.04 
 
Additionally, improvement in QOL was compared between the experimental and control 
groups using mean scores of the WHOQOL questionnaire. The WHOQOL uses 4 domains to 
grade QOL based on physical health (D1), psychological health (D2), social relationships (D3), 
and environment (D4). There was a significant difference between the mean scores in the 
experimental group and the control group after 24-weeks in D1-D3. The experimental group 
showed improvements in mean scores in all 4 domains, while the control group showed a decline 
in all 4 domains.9 The percent increase in the mean scores from baseline to the end of the study 
ranged between 16.3-22.1% for the experimental group.9 AE and data on safety were not 
mentioned in this study. See Table 7 below. 
Table 7. A Comparison of WHOQOL Scores9 
 Baseline (x ± SD) 24 weeks (x ± SD) Mean change from baseline (% increase) 
D1 Sertraline 38.88 ± 11.882a 45.38 ± 11.816e 6.5 (16.7%) 
D1 Control 40 ± 10.997a 33.50 ± 12.635e -6.5 (-16.3%) 
D2 Sertraline 39.50 ± 14.338b 47.23 ± 16.623f 7.73 (19.6%) 
D2 Control 45.30 ± 14.848b 39.13 ± 13.354f -6.17 (-13.6%) 
D3 Sertraline 47.60 ± 15.751c 58.15 ± 18.565g 10.55 (22.1%) 
D3 Control 45.95 ± 14.789c 40.65 ± 20.202g -5.3 (-11.5%) 
D4 Sertraline 37.43 ± 12.683d 43.55 ± 13.027h 6.13 (16.3%) 
D4 Control 44.45 ± 10.261d 39.60 ± 11.845h -4.8 (-10.7%) 
a p= 0.66; b p=0.07; c p=0.6; d p=0.08; e p=0.001; f p=0.01; g p=0.001; h p=0.16 
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DISCUSSION 
  Two RCTs in this review provided statistically significant data supporting the use of 
sertraline as an efficacious drug to decrease depression in post-TBI patients. Unfortunately, the 
study by Ashman, Cantor, Gordon, et al6 did not produce any statistically significant data; 
however, their study was limited by the small sample size (n=41) and the short length of time 
over which the study was conducted (10-weeks). Perhaps if their study were to continue for an 
additional 14-weeks, similarly to the other 24-weeks long studies, their numbers may have 
become statistically significant. It should be noted that the main measure used by Ashman, 
Cantor, Gordon, et al6 was the HAM-D scale, which is a multidimensional measurement of 
depressive symptoms that combines 4 subscales to generate one overall score. Some researchers 
have discounted it as an effective means of determining significant changes in depressive 
symptoms, especially when a medication is used as the intervention. It is thought that 
unidimensional subscales are more sensitive predictors of change when analyzed separately.6 
 Ansari, Jain, Sharma et al.9 found significant improvements in depression and patients 
QOL based on the PHQ-9 and WHOQOL scale, however, it must be highlighted that this study 
did not use blinding, only used male participants, and only used patients with mild or moderate 
TBIs. Therefore, their results cannot be generalized to female patients or those who suffered a 
severe TBI. Jorge, Acion, Burin et al.7 used both female and male participants with mild, 
moderate, and severe TBIs, however 92 of the 94 of the participants were white. Furthermore, 
only 9 out of 94 of their participants sustained a severe TBI.  
 In 2014, there were over 837,000 children responsible for TBI-related ER visits, 
hospitalizations, and deaths in the US11 and the incidence of sports-related concussions (mild 
TBI) is estimated between 1.6 to 3.8 million cases annually3, which makes this a prevalent health 
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issue for many middle and high school athletes. Since this review only discusses studies with 
participants over the age of 18, conclusions drawn from this review may not be consistent with 
the efficacy of this drug in patients who are 17 years old or younger.  
 Sertraline is a commonly used, inexpensive, and safe drug that has been indicated in the 
treatment of depression, anxiety, PTSD, OCD, panic disorder, and premenstrual dysphoric 
disorder. A 25 mg tablet of generic sertraline costs between $2.71 and $2.85 and a 100 mg tablet 
between $2.84 - $2.92 per tablet.10 The three studies in this review used daily dosages of 
sertraline between 25-200 mg, making this a reasonably affordable treatment modality. An 
additional benefit of this medication is the low side effect profile, although some AE do exist. 
Some of the more common side effects of this medication are insomnia, dizziness, restlessness, 
decreased libido, sexual dysfunction, nausea, and diarrhea. It is important to note that a 
contraindication to this medication is the use of sertraline with other drugs that increase levels of 
serotonin in the brain such as MAOIs, including linezolid, methylene blue, and sumatriptan.10 
This could lead to “serotonin syndrome” which is a potentially fatal reaction due to an excessive 
amount of serotonin in the brain leading to hyperthermia, muscle rigidity, alterations in mental 
status and vital signs. It is especially important to note this drug interaction because sumatriptan 
is a medication used for migraines, which may be prescribed to a patient post-TBI.  
Sertraline does have a “US Boxed Warning” worthy of noting, which states, 
“Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young 
adult patients in short-term studies,”.10 Additionally, Beers Criteria considers SSRIs to be 
“potentially inappropriate medications” for patients over the age of 65 due to their associations 
with falls and their ability to potentiate the secretion of ADH. Increased levels of ADH can lead 
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to hyponatremia and, in patients over the age of 65 years old; it is recommended to monitor 
sodium concentrations when initiating treatment with an SSRI or when changing dosages.10 
CONCLUSION 
 Two of the studies in this review provided statistically significant data to support the use 
of sertraline to decrease depression in patients who suffered a TBI. However, when considering 
all three studies, evidence is conflicting. This could be due to flaws in the methodology of these 
studies such as sample size, length of study, and the use of only subjective data in measuring 
depression. All studies consisted of less than 100 participants and no study lasted longer than 6 
months. Future studies should aim to increase sample size, length of intervention, and consider 
the use of both subjective and objective means of measuring depression such as trending BMI, 
cognitive function, change in concentration, and change in sleep. Also, the efficacy of sertraline 
for post-TBI depression in patients under the age of 18 should be considered in future research. 
As previously mentioned, no studies investigated if there were significant differences in 
responses between mild, moderate, or severe TBIs. Also, neither of the three studies sought to 
identify differences in responses based on the mechanism of the TBI such as motor vehicle 
accident, assault, or sports-related injuries. Future studies should seek to compare differences in 
response rates based on severity and mechanism of injury, as well as to compare efficacy based 
on which region of the brain (frontal, temporal, parietal, occipital) was injured as we know these 
areas of the brain have specific functions. Additionally, all studies used sertraline alone as the 
intervention, and it may be useful to identify if any further treatment benefits exist using a 
multidimensional approach such as sertraline plus behavioral therapy or sertraline with TMS or 
ECT. This information would be beneficial to patients and PAs regarding educating patients on 
their prognosis and formulating detailed, efficient, patient-oriented treatment plans. 
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